These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 3392233)

  • 1. Multiple-dose pharmacokinetics of nilvadipine in healthy volunteers.
    Terakawa M; Tokuma Y; Kuwahara N; Shishido A; Noguchi H
    J Clin Pharmacol; 1988 Apr; 28(4):350-5. PubMed ID: 3392233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma levels of (+)- and (-)-nilvadipine after oral dosing with racemic (+)-nilvadipine in man.
    Tokuma Y; Fujiwara T; Noguchi H
    Res Commun Chem Pathol Pharmacol; 1987 Aug; 57(2):229-37. PubMed ID: 3659571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of nilvadipine in healthy volunteers.
    Terakawa M; Tokuma Y; Shishido A; Noguchi H
    J Clin Pharmacol; 1987 Feb; 27(2):111-7. PubMed ID: 3680562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of nilvadipine after single oral doses in healthy volunteers.
    Cheung WK; Woodward DL; Shin K; Hibberd M; Pearse S; Desjardins RE; Yacobi A; Silber BM
    Int J Clin Pharmacol Res; 1988; 8(5):299-305. PubMed ID: 3229870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of nilvadipine, a new dihydropyridine calcium antagonist, in mice, rats, rabbits and dogs.
    Tokuma Y; Sekiguchi M; Niwa T; Noguchi H
    Xenobiotica; 1988 Jan; 18(1):21-8. PubMed ID: 3354229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of rifampicin on the pharmacokinetics and pharmacodynamics of orally administered nilvadipine to healthy subjects.
    Saima S; Furuie K; Yoshimoto H; Fukuda J; Hayashi T; Echizen H
    Br J Clin Pharmacol; 2002 Feb; 53(2):203-6. PubMed ID: 11851646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated plasma nilvadipine concentration after single and chronic oral administration to patients with chronic liver disease.
    Takata Y; Yoshizumi T; Ito Y; Kikuchi M; Ueno M; Tsukashima A; Kobayashi K; Fujishima M
    Eur J Clin Pharmacol; 1992; 42(5):475-9. PubMed ID: 1606993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of two different meals on bioavailability of nilvadipine in healthy volunteers.
    Terakawa M; Tokuma Y; Shishido A; Yasuda K; Noguchi H
    J Clin Pharmacol; 1987 Apr; 27(4):293-6. PubMed ID: 3680587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of oral dosing rate on the hemodynamic and pharmacokinetic profile on nilvadipine.
    Cheung WK; Sia LL; Woodward DL; Graveline JF; Desjardins RE; Yacobi A; Silber BM
    J Clin Pharmacol; 1988 Nov; 28(11):1001-7. PubMed ID: 3243913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between the pharmacokinetic and pharmacodynamic profile of nilvadipine in the dog.
    Wu WH; Henderson BM; Lanc R; Garnes D; Yacobi A; Silber BM
    Drug Metab Dispos; 1988; 16(2):222-7. PubMed ID: 2898337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily.
    Faulkner JK; McGibney D; Chasseaud LF; Perry JL; Taylor IW
    Br J Clin Pharmacol; 1986 Jul; 22(1):21-5. PubMed ID: 2943308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of (+)- and (-)-nilvadipine in human plasma using chiral stationary-phase liquid chromatography and gas chromatography-mass spectrometry, and a preliminary pharmacokinetic study in humans.
    Tokuma Y; Fujiwara T; Noguchi H
    J Pharm Sci; 1987 Apr; 76(4):310-3. PubMed ID: 3598890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system. A controlled-release formulation of nifedipine.
    Chung M; Reitberg DP; Gaffney M; Singleton W
    Am J Med; 1987 Dec; 83(6B):10-4. PubMed ID: 3503594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of nilvadipine.
    von Nieciecki A; Huber HJ; Stanislaus F
    J Cardiovasc Pharmacol; 1992; 20 Suppl 6():S22-9. PubMed ID: 1283185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the clinical pharmacology of nilvadipine in patients with mild to moderate essential hypertension.
    Weir MR; Vlachkis ND; DeQuattro V; Douglas J; Svetkey LP; Singh S; Wiedl SC; Chen CF; Woodward DL; Saunders E
    J Clin Pharmacol; 1990 May; 30(5):425-37. PubMed ID: 2189903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of 3 times a day dosing of oral treprostinil in healthy volunteers.
    Jones A; Wang-Smith L; Pham T; Laliberte K
    J Cardiovasc Pharmacol; 2014 Mar; 63(3):227-32. PubMed ID: 24603117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nilvadipine: profile of a new calcium antagonist. An overview.
    Rosenthal J
    J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S92-107. PubMed ID: 7898101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of a new second generation calcium channel blocker, nilvadipine (FR34235), on exercise-induced hemodynamic changes in stable angina pectoris.
    Yokota M; Koide M; Miyahara T; Kamihara S; Tsunekawa A; Noda S; Sotobata I
    J Am Coll Cardiol; 1987 Oct; 10(4):830-6. PubMed ID: 3655150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbamazepine decreases antihypertensive effect of nilvadipine.
    Yasui-Furukori N; Tateishi T
    J Clin Pharmacol; 2002 Jan; 42(1):100-3. PubMed ID: 11808819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of nifedipine after oral administration in chronic liver disease.
    Ene MD; Roberts CJ
    J Clin Pharmacol; 1987 Dec; 27(12):1001-4. PubMed ID: 3437063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.